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A B S T R A C T   
Infections resulting from Mycobacterium abscessus are increasing in prevalence worldwide, with the greatest risk posed to patients with underlying respiratory 
conditions. Treatment for infections is difficult due to wide ranging intrinsic antimicrobial resistance, which is compounded by the existence of a range of subspecies 
within the M. abscessus complex, each with varying additional antimicrobial resistance profiles. Previously, the use of β-lactam/β-lactamase inhibitors within a 
combination therapy has been proposed as an effective treatment option for pulmonary M. abscessus infections. Here, we assess the in vitro efficacy of two non- 
β-lactam based inhibitors, relebactam and avibactam, as agents against M. abscessus with their respective partner drugs imipenem and ceftazidime, as well as in 
triplicate combinations with additional β-lactam antibiotics against the M. abscessus complex. We have shown that the commercially available ratio of imipenem to 
relebactam is the appropriate ratio for bactericidal activity against M. abscessus, whereas the ratio between ceftazidime and avibactam is redundant, due to inactivity 
of ceftazidime to inhibit the bacteria. We have identified that the use of imipenem and meropenem alongside either relebactam or avibactam yield low minimum 
inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) for each M. abscessus subspecies, which are within the therapeutically achievable 
concentration ranges within the epithelial lining fluid of the lungs. We propose the implementation of imipenem with relebactam in place of stand-alone imipenem 
into the current treatment regime, alongside meropenem, as a future front-line treatment option for M. abscessus complex infections.   
1. Introduction 
Mycobacterium abscessus is an opportunistic human pathogen that is 
an increasing global health threat, capable of causing pulmonary disease 
or skin and soft tissue infections. Of particular susceptibility to these 
infections are those who suffer from cystic fibrosis (CF) or bronchiectasis 
(Viviani et al., 2016, Gardner et al., 2019). High morbidity due to 
M. abscessus infection can be attributed to the difficulty in treatment 
with antimicrobials, largely in part due to the multiple antibiotic resis-
tance mechanisms employed by the pathogen (Lopeman et al., 2019). 
The prolonged treatment regime consists of a combination therapy of 
amikacin, tigecycline and imipenem, as well as clarithromycin or azi-
thromycin (if susceptible) for one month. This is then followed up with a 
combination of clofazimine, linezolid, minocycline, moxifloxacin or co- 
trimoxaole alongside nebulised amikacin, (dependent upon isolate sus-
ceptibility profiling) for 12-months (Haworth et al., 2017, Chen et al., 
2019). The difficulty in isolate susceptibilities is exacerbated by the 
existence of differing subspecies of M. abscessus, which have subtle ge-
netic variations giving rise to phenotypic differences within the popu-
lation. M. abscessus subsp. abscessus is the most common variant, 
whereas M. abscessus subsp. bolletii is the rarest (Adékambi et al., 2006, 
Tortoli et al., 2016, Minias et al., 2020). Both of these subspecies contain 
a functional erm(41) gene encoding for inducible macrolide resistance. 
However, M. abscessus subsp. massiliense does not have a functional erm 
(41) gene, and as such, possesses no resistance to macrolide antibiotics 
(Nash et al., 2009, Luthra et al., 2018, Bordin et al., 2021). It is therefore 
an important consideration to identify subspecies susceptibilities to not 
only the front line treatment options, but also any drug discovery efforts 
to combat M. abscessus. 
A major mechanism of antimicrobial resistance employed by 
M. abscessus is the intrinsic β-lactam resistance provided by expression of 
an endogenous class A β-lactamase, BlaMab, which hydrolyses common 
antibiotics such as penicillin and renders them ineffective (Soroka et al., 
2014). Since the discovery of BlaMab there has been an effort to exploit 
the inhibition of the protein for treatment options (Soroka et al., 2014, 
Dubée et al., 2015). The most promising of these β-lactamase inhibitors 
to date are the non-β-lactam based inhibitors, such as avibactam, rele-
bactam and vaborbactam (Wang et al., 2016, Wong and van Duin, 
2017). These β-lactamase inhibitors have been shown to be effective at 
increasing the susceptibility of M. abscessus to multiple β-lactam anti-
biotics, in particular carbapenems such as meropenem and imipenem 
(Dubée et al., 2015, Kaushik et al., 2019). 
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Avibactam has been demonstrated to be capable of reducing the 
required concentrations of carbapenems down to therapeutically rele-
vant levels in M. abscessus, in particular increasing the susceptibility to 
panipenem, ertapenem and tebipenem (Kaushik et al., 2017). The effi-
cacy of both imipenem and amicakin when used together against 
M. abscessus was also shown to be improved when used in conjunction 
with avibactam (Lefebvre et al., 2017). Previously, we have shown that 
the use of relebactam also increases the susceptibility of M. abscessus to 
amoxicillin, which does not have any effect on the bacteria in the 
absence of the β-lactamase inhibitor. Importantly, this was also seen 
across a panel of clinical M. abscessus isolates (Lopeman et al., 2020). 
In this study, we sought to identify the most potent β-lactamase in-
hibitor combination against the three subspecies of the M. abscessus 
complex, including either relebactam or avibactam. We aim to establish 
the most effective ratios of β-lactam to β-lactamase inhibitor of the 
commercially available formulations for both of these compounds 
against M. abscessus. This research also explores the relationship be-
tween these β-lactamase inhibitors with dual β-lactam partners against 
clinically relevant M. abscessus subspecies, in order to assess the efficacy 
of these triplicate combinations. Our aim for this in vitro assessment is to 
highlight the chemotherapeutic potential of β-lactamase inhibitor 
combinations for treatment of M. abscessus infections and to provide an 
evidence base for the selection of β-lactamase inhibitor combinations. 
2. Materials and methods 
2.1. Bacterial isolates 
M. abscessus NCTC 13031, 15944 subsp. abscessus, DC088A subsp. 
bolletii, DC088D subsp. massiliense were routinely grown in Middlebrook 
7H9 containing 10 % (v/v) Albumin-Dextrose-Catalase (ADC) supple-
ment, 1 % (w/v) glycerol and 0.05 % (w/v) Tween80 and incubated at 
37 ◦C with orbital shaking at 180 rpm. 
2.2. Antimicrobials 
The antimicrobials ceftazidime (CAZ) and amoxicillin (AMX) were 
sourced from Sigma Aldrich (Dorset, UK). Imipenem (IMI), meropenem 
(MER), avibactam (AVI) and relebactam (REL) were obtained from 
Carbosynth (Compton, UK). Stock solutions of all compounds were 
prepared in sterile dH2O, apart from AMX where DMSO was used, and 
stored at − 20 ◦C, where appropriate. 
2.3. Broth microdilution assays 
Broth microdilution assays (or checkerboard assays) were performed 
as previously described, with suitable modifications for this study 
(Lopeman et al., 2020). Briefly, 96-well plates were prepared by serial 
dilution of MER (32, 16, 8, 4, 2, 1, 0.5, 0 µg/mL), AMX (128, 64, 32, 16, 
8, 4, 2, 0 µg/mL), CAZ (24, 12, 6, 3, 1.5, 0.75, 0.375, 0 µg/mL) or IMI 
(24, 12, 6, 3, 1.5, 0.75, 0.375, 0 µg/mL), along the x-axis and either 
CAZ/AVI (48/12, 24/6, 12/3, 6/1.5, 3/0.75, 1.5/0.375, 0.75/0.1875, 
0/0 µg/mL), IMI/REL (24/12, 12/6, 6/3, 3/1.5, 1.5/0.75, 0.75/0.375, 
0.375/0.1875, 0/0 µg/mL), IMI/AVI (24/12, 12/6, 6/3, 3/1.5, 1.5/ 
0.75, 0.75/0.375, 0.375/0.1875, 0/0 µg/mL), AVI (24, 12, 6, 3, 1.5, 
0.75, 0.375, 0 µg/mL), or REL (24, 12, 6, 3, 1.5, 0.75, 0.375, 0 µg/mL), 
along the y-axis, depending upon the compound combination being 
analysed. M. abscessus isolates were diluted to OD600 nm = 0.1 before 
addition to experimental wells at a final volume of 100 µL (n = 4). Plates 
were sealed and incubated at 37 ◦C for 96 h. Spectrophotometric plate 
reads at 570 nm were taken every 24 h. Experimental wells at the 
minimum inhibitory concentration (MIC) were retroactively plotted as 
absorbance vs time using GraphPad Prism 8. The broth microdilution 
assay was repeated for each M. abscessus subspecies (n = 4). 
2.4. Minimum bactericidal concentration evaluation 
The Minimum Bactericidal Concentration (MBC) of each combina-
tion was assessed by 5 µL of each experimental well being spotted onto 
Middlebrook 7H11 agar plates after 96 h growth. The spots were dried 
before incubation of the agar plates at 37 ◦C for 48 h. MBC values were 
determined as the lowest concentrations with an absence of bacterial 
growth. 
3. Results 
3.1. Assessment of β-lactam/β-lactamase inhibitor formulations against 
M. Abscessus 
The β-lactam/β-lactamase inhibitor combinations of IMI/REL and 
CAZ/AVI are pre-formulated at 2:1 and 4:1 ratios respectively (Vazquez 
et al., 2012, Lucasti et al., 2016). However, since these formulations 
were created to treat infections other than those caused by M. abscessus, 
we investigated the role of differing β-lactam/β-lactamase inhibitor ra-
tios against this organism in vitro. Using microbroth dilution checker-
board assays, we assessed different concentrations of IMI and REL as 
well as CAZ and AVI at ratios other than those in which they are pre- 
formulated as. IMI has potent activity against M. abscessus NCTC with 
small concentrations of REL, with activity as low as a ratio of 4:1 (IMI: 
REL) (Fig. 1). This inhibitory activity is beyond that of IMI alone and is 
comparable to the activity of ratios of 2:1 (available formulation), 1:1 
and 1:2 (IMI:REL) (Fig. 1). However, the minimum concentrations at 
which bactericidal activity was observed were 3 µg/mL IMI, 1.5 µg/mL 
REL (2:1 (IMI:REL) ratio), whereas higher concentrations of REL were 
not able to reduce the minimum required concentration of IMI needed to 
sterilise M. abscessus and lower REL concentrations with 3 µg/mL IMI did 
not have bactericidal activity (Table 1). Ratios of CAZ and AVI did not 
have any inhibitory activity against M. abscessus NCTC as high as 4:1 
(combination pre-formulation) (Fig. 1). None of these concentrations 
were bactericidal against M. abscessus (Table 1). 
3.2. Combinations with meropenem 
Using the appropriate pre-formulation ratios of β-lactam to β-lacta-
mase inhibitor partnerships, to provide the most clinically relevant data, 
we aimed to investigate whether these were being complemented by the 
appropriate antimicrobial compound in their respective proposed trip-
licate combinations. We assessed both the combination of CAZ/AVI with 
MER, as well as IMI/REL with MER against each subspecies of 
M. abscessus in order to evaluate the combination that could provide the 
best clinical application. The lowest MIC of MER at 1 µg/mL was ach-
ieved by combination with IMI/REL at 0.75 µg/mL/0.375 µg/mL 
respectively for every subspecies; M. abscessus NCTC, M. abscessus subsp. 
abscessus, M. abscessus subsp. bolletii and M. abscessus subsp. massiliense 
(Fig. 2). The concentrations of IMI (0.75 µg/mL) and REL (0.375 µg/mL) 
without MER were not sufficient to completely inhibit growth of any of 
M. abscessus subsp., as was also the case for MER only (1 µg/mL) (Fig. 2). 
These combination concentrations are bactericidal, yielding combined 
minimum bactericidal concentrations (MBCs) of 0.75 µg/mL IMI, 0.375 
Fig. 1. Growth curves of M. abscessus NCTC 13031 with varying β-lactam/ 
β-lactamase inhibitor combination ratios. A) Varying ratios of imipenem (IMI) 
and relebactam (REL) (p ≤ 0.0001, n = 4). B) Varying ratios of ceftazidime 
(CAZ) and avibactam (AVI) (p = 0.5287, n = 4). 
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µg/mL REL and 1 µg/mL MER in each subspecies of M. abscessus 
(Table 1). 
In conjunction with CAZ/AVI, the lowest MIC of MER was 2 µg/mL at 
0.75 µg/mL and 0.1875 µg/mL for CAZ and AVI respectively. These 
concentrations were required for the inhibition of M. abscessus NCTC, 
M. abscessus subsp. abscessus and M. abscessus subsp. bolletii (Fig. 3). 
However, slightly higher concentration of MER (4 µg/mL) was required 
to inhibit growth of M. abscessus subsp. massiliense at the equivalent 
concentrations of CAZ/AVI as the other subspecies (Fig. 3). In all sub-
species, MER (at 2 µg/mL and 4 µg/mL) in the absence of CAZ and AVI 
resulted in some inhibition of bacterial growth, but not to the extent of 
the triplicate combination, whereas CAZ/AVI in the absence of MER 
resulted in no reduction in growth (Fig. 3). Concentrations of 0.75 µg/ 
mL CAZ, 0.1875 µg/mL AVI and 2 µg/mL MER were bactericidal against 
each M. abscessus subspecies, apart from M. abscessus subsp. massiliense 
which required 4 µg/mL MER at the equivalent concentrations of CAZ 
and AVI (0.75 µg/mL and 0.1875 µg/mL respectively) (Table 1). 
Given the efficacy of MER as a companion β-lactam with both IMI/ 
REL and CAZ/AVI, an assessment of AVI with IMI (1:2 respectively) was 
made versus MER. MICs of 0.375 µg/mL for IMI, 0.1875 µg/mL for AVI 
and 0.5 µg/mL for MER were recorded for M. abscessus NCTC, 
M. abscessus subsp. abscessus and M. abscessus subsp. bolletii (Fig. 4). 
Slightly higher concentrations of both IMI (0.75 µg/mL) and AVI (0.375 
µg/mL) were required against M. abscessus subsp. massiliense (Fig. 4). 
IMI with AVI at 0.375 µg/mL and 0.1875 µg/mL, respectively, were able 
to inhibit the growth of all M. abscessus subspecies, but not to the extent 
as when combined with MER (Fig. 4). However, MER alone at 0.5 µg/mL 
was not sufficient to greatly inhibit the growth of any of M. abscessus 
(Fig. 4). These concentrations were bactericidal against each corre-
sponding M. abscessus subspecies (Table 1). 
Table 1 
Minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) of each component of assessed drug combinations against M. abscessus 
complex.  
M. abscessus subspecies 
Drug (combo) NCTC subsp. abscessus subsp. bolletii subsp. massiliense 
MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL) 
CAZ >48 >48 >48 >48 >48 >48 >48 >48 
IMI 3 3 1.5 3 3 3 1.5 6 
MER 6 6 6 6 12 24 12 12 
AMX >128 >128 >128 >128 >128 >128 >128 >128 
CAZ/AVI >48/>24 >48/>24 >48/>24 >48/>24 >48/>24 >48/>24 >48/>24 >48/>24 
IMI/MER 1.5/1.5 1.5/1.5 0.375/1.5 1.5/0.75 1.5/3 1.5/0.75 0.75/1.5 1.5/3 
CAZ/AVI (MER) 0.75/0.1875 0.75/0.1875 0.75/0.1875 0.75/0.1875 0.75/0.1875 0.75/0.1875 0.75/0.1875 0.75/0.1875 
CAZ/AVI (IMI) 1.5/0.375 0.75/0.1875 0.75/0.1875 0.75/0.1875 0.75/0.1875 0.75/0.1875 0.75/0.1875 0.75/0.1875 
CAZ/AVI (AMX) 3/0.75 3/0.75 1.5/0.375 1.5/0.375 6/1.5 6/1.5 3/0.75 3/0.75 
MER (CAZ/AVI) 2 2 2 2 2 2 4 4 
IMI (CAZ/AVI) 1.5 3 1.5 3 1.5 3 1.5 6 
AMX (CAZ/AVI) 8 8 16 16 16 16 16 16 
IMI/REL 0.375 3/1.5 0.375 6/0.375 1.5/0.375 6/0.375 1.5/1.5 12/0.75 
IMI/REL (MER) 0.75/0.375 0.75/0.375 0.75/0.375 0.75/0.375 0.75/0.375 0.75/0.375 0.75/0.375 0.75/0.375 
IMI/REL (AMX) 1.5/0.75 1.5/0.75 1.5/0.75 1.5/0.75 1.5/0.75 3/1.5 3/1.5 6/3 
MER (IMI/REL) 1 1 1 1 1 1 1 1 
AMX (IMI/REL) 8 16 16 64 64 128 16 0 
IMI/AVI 3/1.5 0.75/0.375 3/1.5 0.75/0.375 6/3 0.75/0.375 3/1.5 1.5/0.75 
IMI/AVI (MER) 0.375/0.1875 0.375/0.1875 0.375/0.1875 0.375/0.1875 0.375/0.1875 0.375/0.1875 0.75/0.375 0.75/0.375 
IMI/AVI (AMX) 1.5/0.75 1.5/0.75 0.75/0.375 1.5/0.75 1.5/0.75 1.5/0.75 1.5/0.75 1.5/0.75 
MER (IMI/AVI) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
AMX (IMI/AVI) 8 8 16 16 16 32 32 32  
Fig. 2. Growth curves of M. abscessus subspecies with imipenem (IMI)/rele-
bactam (REL) vs meropenem (MER). Endpoint solid media bacterial re-growth 
is shown at the end of each curve. A) M. abscessus NCTC 13031 with an MIC of 
0.75 µg/mL IMI, 0.375 µg/mL REL and 1 µg/mL MER (p ≤ 0.0001, n = 4). B) 
M. abscessus subsp. abscessus with an MIC of 0.75 µg/mL IMI, 0.375 µg/mL REL 
and 1 µg/mL MER (p ≤ 0.0001, n = 4). C) M. abscessus subsp. bolletii with an 
MIC of 0.75 µg/mL IMI, 0.375 µg/mL REL and 1 µg/mL MER (p ≤ 0.0001, n =
4). D) M. abscessus subsp. massiliense with an MIC of 0.75 µg/mL IMI, 0.375 µg/ 
mL REL and 1 µg/mL MER (p ≤ 0.0001, n = 4). 
Fig. 3. Growth curves of M. abscessus subspecies with ceftazidime (CAZ)/avi-
bactam (AVI) vs meropenem (MER). Endpoint solid media bacterial re-growth 
is shown at the end of each curve. A) M. abscessus NCTC 13031 with an MIC of 
0.75 µg/mL CAZ, 0.1875 µg/mL AVI and 2 µg/mL MER (p ≤ 0.0001, n = 4). B) 
M. abscessus subsp. abscessus with an MIC of 0.75 µg/mL CAZ, 0.1875 µg/mL 
AVI and 2 µg/mL MER (p ≤ 0.0001, n = 4). C) M. abscessus subsp. bolletii with 
an MIC of 0.75 µg/mL CAZ, 0.1875 µg/mL AVI and 2 µg/mL MER (p ≤ 0.0001, 
n = 4). D) M. abscessus subsp. massiliense with an MIC of 0.75 µg/mL CAZ, 
0.1875 µg/mL AVI and 4 µg/mL MER (p ≤ 0.0001, n = 4). 
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3.3. Amoxicillin combinations 
Since these β-lactamase inhibitors have been shown to increase the 
susceptibility of M. abscessus to AMX, we then investigated the efficacies 
of both CAZ/AVI with AMX and IMI/REL with AMX against the 
M. abscessus subspecies. We identified that the MIC for M. abscessus 
NCTC required 3 µg/mL CAZ, 0.75 µg/mL AVI, along with 8 µg/mL 
AMX, which was not the same for M. abscessus subsp. abscessus, which 
required 1.5 µg/mL CAZ, 0.375 AVI and 16 µg/mL AMX (Fig. 5). 
M. abscessus subsp. massiliense required slightly more AMX than 
M. abscessus NCTC (16 µg/mL), but the same concentrations of CAZ and 
AVI (Fig. 5). However, M. abscessus subsp. bolletii required higher con-
centrations than the other subspecies for each combination compound, 
with an MIC of 6 µg/mL CAZ, 1.5 µg/mL AVI with 16 µg/mL AMX 
(Fig. 5). Neither CAZ/AVI alone (up to 6 µg/mL and 1.5 µg/mL) nor AMX 
alone (up to 16 µg/mL) were capable of inhibiting bacterial growth 
(Fig. 5). These combined MIC concentrations were all bactericidal in 
each corresponding M. abscessus subspecies (Table 1). 
This trend is similarly seen when assessing the combination of IMI/ 
REL with AMX against each of the M. abscessus subspecies. The con-
centrations of IMI/REL required at the MIC for M. abscessus NCTC are 
much lower than that of CAZ/AVI (1.5 µg/mL and 0.75 µg/mL respec-
tively), however the same concentration of AMX is needed (8 µg/mL) 
(Fig. 6). The MIC of AMX required then increased for the remaining 
subspecies, 16 µg/mL for M. abscessus subsp. abscessus and 64 µg/mL for 
M. abscessus subsp. bolletii, with the same concentrations of IMI/REL. 
However, M. abscessus subsp. massiliense required an increase in IMI/ 
REL concentration to 3 µg/mL and 1.5 µg/mL respectively, alongside 16 
µg/mL AMX (Fig. 6). IMI and REL alone (at concentrations of both 1.5 
µg/mL/0.75 µg/mL (IMI/REL) and 3 µg/mL/1.5 µg/mL) were able to 
inhibit the growth of all M. abscessus subspecies, however not to the 
extent of the triplicate combination (Fig. 6). Conversely, AMX alone (up 
to 64 µg/mL) was not sufficient to inhibit the growth of M. abscessus 
(Fig. 6). The concentrations of IMI/REL and AMX required to become 
bactericidal are increased from the MIC values. Concentrations of 1.5 
µg/mL IMI, 0.75 µg/mL REL and 16 µg/mL AMX are required to be lethal 
to M. abscessus NCTC, whereas 64 µg/mL is needed against M. abscessus 
subsp. abscessus. An increase of all concentrations are required to be 
bactericidal against M. abscessus subsp. bolletii, to 3 µg/mL IMI, 1.5 µg/ 
mL REL and 128 µg/mL AMX (Table 1). Interestingly, there is no benefit 
to the inclusion of AMX in the combination to be bactericidal against 
M. abscessus subsp. massiliense, since the MBC is 6 µg/mL IMI, 3 µg/mL 
REL and 0 µg/mL AMX (Table 1). 
We also investigated the efficacy of IMI in partnership with AVI (2:1) 
versus AMX against the M. abscessus subspecies. MIC values were largely 
comparable to those of IMI/REL with AMX, with some variation in 
concentration of AMX across the subspecies. Concentrations of 1.5 µg/ 
mL IMI, 0.75 µg/mL AVI and 8 µg/mL AMX were required to inhibit 
M. abscessus NCTC, whereas 16 µg/mL and 32 µg/mL AMX were 
required to inhibit growth of M. abscessus subsp. bolletii and M. abscessus 
subsp. massiliense respectively, at the same IMI/AVI concentrations 
(Fig. 7). Slightly lower concentrations of IMI and AVI (0.75 µg/mL and 
0.375 µg/mL respectively) alongside 16 µg/mL AMX were needed to 
inhibit the growth of M. abscessus subsp. abscessus (Fig. 7). In the absence 
of AMX, IMI and AVI alone were able to slightly inhibit growth of 
M. abscessus subspecies at concentrations of 1.5 µg/mL IMI and 0.75 µg/ 
mL AVI, however, not to the extent of inhibition seen with the addition 
of AMX (Fig. 7). Conversely, AMX (up to 32 µg/mL) was not able to 
inhibit the growth of M. abscessus alone (Fig. 7). The concentrations 
required to be bactericidal against M. abscessus subspecies were 1.5 µg/ 
mL IMI, 0.75 AVI and 8 µg/mL AMX against M. abscessus NCTC and 1.5 
µg/mL IMI, 0.75 AVI and 16 µg/mL AMX against M. abscessus subsp. 
abscessus. However, a slightly higher concentration of AMX (32 µg/mL) 
was required to sterilise M. abscessus subsp. bolletii and M. abscessus 
Fig. 4. Growth curves of M. abscessus subspecies with imipenem (IMI)/avi-
bactam (AVI) vs meropenem (MER). Endpoint solid media bacterial re-growth 
is shown at the end of each curve. A) M. abscessus NCTC 13031 with an MIC of 
0.375 µg/mL IMI, 0.1875 µg/mL AVI and 0.5 µg/mL MER (p ≤ 0.0001, n = 4). 
B) M. abscessus subsp. abscessus with an MIC of 0.375 µg/mL IMI, 0.1875 µg/mL 
AVI and 0.5 µg/mL MER (p ≤ 0.0001, n = 4). C) M. abscessus subsp. bolletii with 
an MIC of 0.375 µg/mL IMI, 0.1875 µg/mL AVI and 0.5 µg/mL MER (p ≤
0.0001, n = 4). D) M. abscessus subsp. massiliense with an MIC of 0.75 µg/mL 
IMI, 0.1875 µg/mL AVI and 0.5 µg/mL MER (p ≤ 0.0001, n = 4). 
Fig. 5. Growth curves of M. abscessus subspecies with ceftazidime (CAZ)/avi-
bactam (AVI) vs amoxicillin (AMX). Endpoint solid media bacterial re-growth is 
shown at the end of each curve. A) M. abscessus NCTC 13031 with an MIC of 3 
µg/mL CAZ, 0.75 µg/mL AVI and 8 µg/mL AMX (p ≤ 0.0001, n = 4). B) 
M. abscessus subsp. abscessus with an MIC of 1.5 µg/mL CAZ, 0.375 µg/mL AVI 
and 16 µg/mL AMX (p ≤ 0.0001, n = 4). C) M. abscessus subsp. bolletii with an 
MIC of 6 µg/mL CAZ, 1.5 µg/mL AVI and 16 µg/mL AMX (p ≤ <0.0001, n = 4). 
D) M. abscessus subsp. massiliense with an MIC of 3 µg/mL CAZ, 0.75 µg/mL AVI 
and 16 µg/mL AMX (p ≤ 0.0001, n = 4). 
Fig. 6. Growth curves of M. abscessus subspecies with imipenem (IMI)/rele-
bactam (REL) vs amoxicillin (AMX). Endpoint solid media bacterial re-growth is 
shown at the end of each curve. A) M. abscessus NCTC 13031 with an MIC of 1.5 
µg/mL IMI, 0.75 µg/mL REL and 8 µg/mL AMX (p ≤ 0.0001, n = 4). B) 
M. abscessus subsp. abscessus with an MIC of 1.5 µg/mL IMI, 0.75 µg/mL REL 
and 16 µg/mL AMX (p ≤ 0.0001, n = 4). C) M. abscessus subsp. bolletii with an 
MIC of 1.5 µg/mL IMI, 0.75 µg/mL REL and 64 µg/mL AMX (p ≤ 0.0001, n = 4). 
D) M. abscessus subsp. massiliense with an MIC of 3 µg/mL IMI, 1.5 µg/mL REL 
and 16 µg/mL AMX (p ≤ 0.0001, n = 4). 
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subsp. massiliense with the same concentrations of IMI (1.5 µg/mL) and 
AVI (0.75 µg/mL) (Table 1). 
3.4. Imipenem combinations 
Since IMI is a frontline antimicrobial used against M. abscessus 
infection, further investigation into the relationship between IMI and 
CAZ/AVI was necessitated. We assessed the efficacy against each 
M. abscessus subspecies and the MIC for M. abscessus subsp. abscessus, 
M. abscessus subsp. bolletii and M. abscessus subsp. massiliense was 0.75 
µg/mL CAZ, 0.1875 µg/mL AVI and 1.5 µg/mL IMI (Fig. 8). A higher 
concentration of CAZ (1.5 µg/mL) and AVI (0.375 µg/mL) was needed to 
inhibit the growth of M. abscessus NCTC with the same concentration of 
IMI (1.5 µg/mL) as other subspecies (Fig. 8). For each subspecies, CAZ 
and AVI alone (up to 1.5 µg/mL and 0.375 µg/mL respectively) does not 
inhibit growth, however, IMI alone at 1.5 µg/mL does provide some 
growth inhibition, but less than the triplicate combination (Fig. 8). 
Higher concentrations of IMI are required for bactericidal activity 
against each subspecies, with MBCs of 0.75 µg/mL CAZ, 0.1875 µg/mL 
AVI and 3 µg/mL IMI. For M. abscessus subsp. massiliense, 6 µg/mL IMI is 
required alongside 0.75 µg/mL CAZ and 0.1875 µg/mL AVI in order to 
sterilise the bacteria (Table 1). 
4. Discussion 
The M. abscessus complex comprises of multiple subspecies of bac-
teria that are responsible for highly antimicrobial resistant infections, 
which are difficult to successfully treat. We have evaluated the β-lac-
tamase inhibitors REL and AVI, both of which are highly effective agents 
which vastly increase the efficacy of β-lactams against each subspecies of 
the M. abscessus complex. We explored the optimal ratios of β-lactam 
partner agent to β-lactamase inhibitor against M. abscessus, in order to 
ascertain whether the commercially available formulations of IMI with 
REL and CAZ with AVI performed sub-optimally. We identified that REL 
was an effective β-lactamase inhibitor in conjunction with IMI down to a 
ratio of 2:1 (IMI:REL), which is the available pre-formulation (Fig. 1). 
The increase in REL concentration to IMI (1:1 and 1:2 (IMI:REL) ratios) 
was not sufficient to reduce the required inhibitory concentrations of 
IMI below 0.75 µg/mL, nor to reduce the bactericidal concentration 
below 3 µg/mL. Increasing the IMI:REL ratio to 4:1 allowed for the 
inhibitory concentration of IMI to remain at 0.75 µg/mL, but was not 
sufficient to sterilise the M. abscessus at 3 µg/mL of IMI. Therefore, the 
pre-formulated ratio of 2:1 (IMI:REL) is the most potent choice for ac-
tivity against M. abscessus, as it provides the lowest dosing concentra-
tions, whilst maintaining the most effective bactericidal activity of each 
assessed ratio. Conversely, we concluded that CAZ has no effect on the 
growth of M. abscessus at any ratio with AVI, therefore rendering the 
ratio used redundant in terms of treatment of M. abscessus infections. 
Each triplicate combination that was assessed was capable of steri-
lising M. abscessus complex members down to low, therapeutically 
viable concentrations in vitro (Table 1). However, the most effective 
combination in terms of lowest combined MIC and MBC values was the 
grouping of IMI/AVI with MER, with concentrations of 0.375 µg/mL, 
0.1875 µg/mL and 0.5 µg/mL respectively, for almost each subspecies 
(Fig. 4). This was closely followed by the combination of IMI/REL with 
MER, with combined concentrations of 0.75 µg/mL, 0.375 µg/mL and 1 
µg/mL respectively for every M. abscessus subspecies (Fig. 2). The 
addition of CAZ/AVI to IMI also yields MIC values within a similar 
range, with combination concentrations of 0.75 µg/mL, 0.1875 µg/mL 
and 1.5 µg/mL respectively (Fig. 8). Conversely, the MBC values for this 
combination require a higher concentration of IMI (up to 6 µg/mL) for 
sterilisation of M. abscessus (Table 1). However, replacing IMI with 2 µg/ 
mL MER in combination with CAZ/AVI results in bactericidal activity 
against all but one of the M. abscessus subspecies (Table 1). The con-
centrations of these combinations are much lower than the required 
inhibitory and bactericidal concentrations for IMI and MER both as in-
dependent agents, and also in combination with each other in the 
absence of a β-lactamase inhibitor (Table 1). Each combination of 
β-lactamase inhibitor increased the susceptibility of the M. abscessus 
complex to AMX, but at significantly higher concentrations of AMX 
(between 8 and 32 µg/mL) than when compared to either IMI or MER as 
an additional companion β-lactam (Table 1). 
Each of these concentrations are achievable within the epithelial 
lining fluid (ELF), within the lungs where the majority of M. abscessus 
infections occur. Specifically, the maximum concentration of MER after 
multiple doses in the ELF is ~7.07 µg/mL, whereas IMI is ~9.76 µg/mL 
(Allegranzi et al 2000, Rizk et al., 2018). Furthermore, the maximum 
concentration of AVI in the ELF during standard treatment is ~5.1 µg/ 
mL, which is comparable to REL at ~5.33 µg/mL (Nicolau et al 2015, 
Rizk et al., 2018). The concentration of CAZ that can be reached in ELF 
is ~23.2 µg/mL, whereas AMX has a maximum ELF concentration of 
~0.89 µg/mL (Nicolau et al 2015, Cook et al 1994) It is therefore 
possible for each of these combinations to reach a clinically relevant 
concentration during treatment, since those combinations with higher 
AMX MIC/MBCs can be driven to within the range for ELF penetration 
with an increase to their respective β-lactam/β-lactamase inhibitor 
partners (Lopeman et al., 2020). As a frontline treatment drug for 
Fig. 7. Growth curves of M. abscessus subspecies with imipenem (IMI)/avi-
bactam (AVI) vs amoxicillin (AMX). Endpoint solid media bacterial re-growth is 
shown at the end of each curve. A) M. abscessus NCTC 13031 with an MIC of 1.5 
µg/mL IMI, 0.75 µg/mL AVI and 8 µg/mL AMX (p ≤ =<0.0001, n = 4). B) 
M. abscessus subsp. abscessus with an MIC of 0.75 µg/mL IMI, 0.375 µg/mL AVI 
and 16 µg/mL AMX (p ≤ 0.0001, n = 4). C) M. abscessus subsp. bolletii with an 
MIC of 1.5 µg/mL IMI, 0.75 µg/mL AVI and 16 µg/mL AMX (p ≤ 0.0001, n = 4). 
D) M. abscessus subsp. massiliense with an MIC of 1.5 µg/mL IMI, 0.75 µg/mL 
AVI and 32 µg/mL AMX (p ≤ 0.0001, n = 4). 
Fig. 8. Growth curves of M. abscessus subspecies with ceftazidime (CAZ)/avi-
bactam (AVI) vs imipenem (IMI). Endpoint solid media bacterial re-growth is 
shown at the end of each curve. A) M. abscessus NCTC 13031 with an MIC of 1.5 
µg/mL CAZ, 0.375 µg/mL AVI and 1.5 µg/mL IMI (p ≤ 0.0001, n = 4). B) 
M. abscessus subsp. abscessus with an MIC of 0.75 µg/mL CAZ, 0.1875 µg/mL 
AVI and 1.5 µg/mL IMI (p ≤ 0.0001, n = 4). C) M. abscessus subsp. bolletii with 
an MIC of 0.75 µg/mL CAZ, 0.1875 µg/mL AVI and 1.5 µg/mL IMI (p ≤ 0.0001, 
n = 4). D) M. abscessus subsp. massiliense with an MIC of 0.75 µg/mL CAZ, 
0.1875 µg/mL AVI and 1.5 µg/mL IMI (p ≤ 0.0001, n = 4). 
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M. abscessus infection, it is plausible for combinations containing IMI to 
be implemented into the current treatment regime. However, since AVI 
is available only pre-formulated with CAZ (at a ratio of 4:1), rather than 
alone, any use of this β-lactamase inhibitor would include an excessive 
dosing of an unnecessary antibiotic which has numerous avoidable side- 
effects, the most extreme of which include seizures and severe skin re-
actions (Shirley 2018). Conversely, since REL is pre-formulated with IMI 
(and cilastatin), the additional antimicrobial burden on the patient is 
minimised, since IMI (with cilastatin) will be administered regardless 
within the frontline treatment regime for M. abscessus infections. The 
combination of IMI and REL has no additional side effects beyond those 
of IMI alone, so it is therefore a rational argument to utilise IMI and REL 
in place of IMI alone, alongside the implementation of MER, to limit the 
unnecessary drug burden of patients and successfully achieve bacteri-
cidal concentrations to sterilise M. abscessus infections. Therefore, we 
propose the use of IMI, REL and MER as the best option, from the 
combinations we have assessed, to potentially treat M. abscessus com-
plex infections, because of the low MIC and MBC values yielded, as well 
as the best option for patient quality of life in terms of overall antimi-
crobial burden. 
5. Conclusions 
We have identified that the combinations of IMI, AVI and MER and 
IMI, REL and MER are the best triplicate combinations that we tested. 
These combinations yielded low MIC/MBC values of 0.375 µg/mL IMI, 
0.1875 µg/mL AVI, 0.5 µg/mL MER and 0.75 µg/mL IMI, 0.375 µg/mL 
REL and 1 µg/mL MER. However, due to the fact that AVI is only 
available in a pre-formulation with CAZ (at a 4:1 ratio), there would be 
excessive additional antibiotic burden on patients that would not be the 
case with REL, since it is available pre-formulated with IMI. Therefore, 
the use of IMI, REL and MER against members of the M. abscessus 
complex is an appropriate choice based upon patient quality of life and 
sterilisation of M. abscessus infections. 
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